Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Illumina
| Name of system | NextSeq 550Dx |
|---|---|
| Company | Illumina |
| City, State | San Diego, CA |
| Phone | 858-202-4500 |
| Website | |
| System application/FDA cleared or approved | in vitro diagnostic and research use/yes |
| Country where designed/Manufactured | U.S./Singapore |
| First year sold in U.S./First year installed in U.S. | 2017/2017 |
| System sold internationally | yes (Canada, Europe, Greater China, Asia Pacific, more) |
| Dimensions of sequencer (H × W × D)/Footprint of sequencer | — |
| Accessory equipment supplied with sequencer at no cost | — |
| Type of computer supplied with sequencer | computer for analysis and operations combined |
| Analysis options provided with sequencer | onboard, cloud based |
| Where library preparation is performed | accessory equipment, wet bench |
| Bioinformatics tools provided with sequencer | onboard, cloud based |
| Sequencer supplied with UPS (uninterruptible power supply) | no |
| Electrical connection required for sequencer | 100–120 VAC at 50/60 Hz |
| List price of entire sequencer and necessary components | $347,000 |
| Purchase options | purchase, trade in, lease, reagent rental |
| Warranties offered | first year included with purchase; extended warranty available |
| Training included/Total time for basic training per operator | yes/2 days |
| Training location/Follow-up training available | at customer site/yes (extra charge) |
| Maximum No. of samples amplified in a single amplification event | 384 samples (>384 samples with custom barcodes) |
| Read length/Percent bases >Q30 | yes/2 × 150 bp/up to 350 bp |
| Paired-end capability/Tag lengths/Spans | yes/2 × 150 bp/up to 350 bp |
| Fragment/Tag lengths/Spans | yes/2 × 150 bp/up to 350 bp |
| Mate pair/Tag lengths/Spans | yes/2 × 150 bp/2–12 kb |
| Single end/Tag lengths/Spans | yes/up to 1 × 300 bp/up to 300 bp |
| RNA sequencing/Tag lengths/Spans | yes/up to 2 × 150 bp/up to 350 bp |
| ChIP sequencing/Tag lengths/Spans | yes/up to 2 × 150 bp/up to 350 bp |
| Bisulfite sequencing/Tag lengths/Spans | yes/up to 2 × 150 bp/up to 350 bp |
| Maximum No. of reads or fragments sequenced per single-end run | >300 million |
| Maximum No. of reads or fragments sequenced per paired-end run | >600 million |
| Total No. of nucleotides (bases) sequenced per run | up to 120 gb |
| Wet lab bench time for sequencing preparation | 10 minutes |
| Sequencing run time | <36 hours |
| Total time for generating standard gDNA library | <3.5 hours (with Illumina DNA Prep) |
| • Paired end | <3.5 hours (with Illumina DNA Prep) |
| • Fragment | <7 hours (with AmpliSeq for Illumina); <6.5 hours (with Illumina DNA Prep with Enrichment) |
| • Paired end | |
| • Fragment | <1.5 hours (with AmpliSeq for Illumina); <2 hours (with Illumina DNA Prep with Enrichment) |
| • Mate pair | — |
| • Single end | <4 hours (with TruSeq Small RNA) |
| • RNA sequencing | <3 hours |
| • ChIP sequencing | — |
| • Bisulfite sequencing | — |
| Library preparation integrated in system as standard offering | no |
| Library preparation offered separately for additional charge | no |
| Cost of sequencing reagents per run | — |
| Reagent tracking method | RFID |
| • Type of reagent information tracked | serial No., expiration date, lot and part Nos., No. of cycles |
| Shipping conditions for amplification/sequencing reagents | — |
| Storage conditions for amplification/sequencing reagents | —/reagent cartridge, HT1 buffer: -15°– -25°C; flow cell: 2°–8°C; buffer cartridge: 15°–30°C |
| Shelf life of amplification/sequencing reagents | guaranteed 3 months/guaranteed 3 months |
| System requires a control sample on sequencing run | yes |
| • Company offers a sequencing control | yes (additional charge) |
| Sequencing system control software and devices to start run/for data analysis | NextSeq 550Dx Control Software and Operating Software/Local Run Manager, BaseSpace Sequence Hub |
| Complete walkaway automation for amplification, sequencing, and variant calling | yes |
| Remote system monitoring | yes |
| Total time required for setup of amplification, sequencing, and variant calling steps | 10 minutes |
| Maximum No. of libraries sequenced in a single run | 384 samples (>384 samples with custom barcodes) |
| System includes secondary data-analysis software developed by company | yes (BaseSpace Sequence Hub) |
| System includes post-sequencing data-analysis software | yes |
| Mutations detectable via data-analysis software | substitutions, indels, copy number changes |
| System can generate a variant report | yes |
| Types of maintenance plans available/mean time between failures | parts only, bronze, silver, gold, Dx, dedicated on-site/— |
| No. of field application scientists and engineers based in U.S. | >500 |
| • Weekly | none (manual wash if instrument idle for 2 weeks) |
| • Monthly | none |
| • Pre-run | none (automatic wash completed after every run) |
| Distinguishing features of NGS system (supplied by company)Note: a dash in lieu of an answer means company did not answer question or question is not applicable | analyzes solid tumors using minimal tissue with TruSight Oncology Comprehensive, a reimbursable, validated, FDA-cleared test for in vitro diagnostics; runs IVD assays and laboratory-developed tests; 21 CFR part 11 compliant software |